Cytokine release syndrome: Difference between revisions
From IDWiki
mNo edit summary |
(→) |
||
| Line 6: | Line 6: | ||
* Fever, hypotension, tachypnea, tachycardia, headache, rash, dyspnea, hypoxemia |
* Fever, hypotension, tachypnea, tachycardia, headache, rash, dyspnea, hypoxemia |
||
* With BiTE, most common after first dose or first few doses |
|||
* Time of onset is variable |
|||
** CAR-T: 2-3 days (range 1 to 14 days) |
|||
** Haploidentical HSCT: 1 to 3 days |
|||
** Bispecific antibodies: usually within 24-48 hours (range from minutes up to 9 days) |
|||
=== Prognosis === |
|||
* Usually resolves within a few days to a few weeks |
|||
== ASTCT CRS Grading[[CiteRef::lee2019as]] == |
== ASTCT CRS Grading[[CiteRef::lee2019as]] == |
||
| Line 37: | Line 46: | ||
|Positive-pressure ventilation (non-invasive or invasive) |
|Positive-pressure ventilation (non-invasive or invasive) |
||
|} |
|} |
||
== Management == |
|||
* Grade 2-4: [[Tocilizumab]] 8 mg/kg (max 800 mg), can be repeated q8h up to 4 doses; plus [[dexamethasone]] 10 mg QID |
|||
[[Category:Hematology]] |
[[Category:Hematology]] |
||
[[Category:Oncology]] |
[[Category:Oncology]] |
||
Revision as of 02:06, 26 March 2024
Background
Clinical Manifestations
- Fever, hypotension, tachypnea, tachycardia, headache, rash, dyspnea, hypoxemia
- With BiTE, most common after first dose or first few doses
- Time of onset is variable
- CAR-T: 2-3 days (range 1 to 14 days)
- Haploidentical HSCT: 1 to 3 days
- Bispecific antibodies: usually within 24-48 hours (range from minutes up to 9 days)
Prognosis
- Usually resolves within a few days to a few weeks
ASTCT CRS Grading1
| Parameter | Grade 1 | Grade 1 | Grade 3 | Grade 4 |
|---|---|---|---|---|
| Fever | ≥38ºC | ≥38ºC | ≥38ºC | ≥38ºC |
| with | ||||
| Hypotension | — | Not on vasopressors | One vasopressor ± vasopressin | Multiple vasopressors |
| and/or | ||||
| Hypoxia | — | Low-flow nasal cannula | High-flow nasal cannula, facemask, nonrebreather mask, Venturi mask | Positive-pressure ventilation (non-invasive or invasive) |
Management
- Grade 2-4: Tocilizumab 8 mg/kg (max 800 mg), can be repeated q8h up to 4 doses; plus dexamethasone 10 mg QID
References
- ^ Daniel W. Lee, Bianca D. Santomasso, Frederick L. Locke, Armin Ghobadi, Cameron J. Turtle, Jennifer N. Brudno, Marcela V. Maus, Jae H. Park, Elena Mead, Steven Pavletic, William Y. Go, Lamis Eldjerou, Rebecca A. Gardner, Noelle Frey, Kevin J. Curran, Karl Peggs, Marcelo Pasquini, John F. DiPersio, Marcel R.M. van den Brink, Krishna V. Komanduri, Stephan A. Grupp, Sattva S. Neelapu. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758.
